Year All2024202320222021202020192018201720162015201420122011 May 17, 2023 Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) May 15, 2023 Ardelyx, Inc. Reports Employment Inducement Grants May 9, 2023 Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults May 3, 2023 Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update May 1, 2023 Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference Apr 26, 2023 Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023 Apr 18, 2023 Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor) Apr 13, 2023 Ardelyx, Inc. Reports Employment Inducement Grants Apr 12, 2023 Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings Mar 2, 2023 Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update